Aim: This paper systematically reviews clinical trials investigating the effectiveness of cognitive behavioural therapy for insomnia and pain in patients with chronic non-malignant pain. Method: A systematic search of MEDLINE, PSYCINFO, EMBASE, CINHAL and Cochrane library and register of trials was conducted. Results: Essential components of cognitive behavioural therapy for insomnia were included in all studies except for the cognitive restructuring component, which was not considered an intervention in one study. Interventions were provided by adequately trained clinicians. Significant within-group effect sizes (> 1) were observed in the intervention groups as compared with the control groups. Improvements were noted in sleep latency, sleep efficiency and wake after sleep onset times. Although improvements were noted in pain experienced by the participants, this was not a significant finding. Conclusions: These clinical trials demonstrate that cognitive behavioural therapy for insomnia is effective as an intervention for insomnia in individuals suffering from chronic non-malignant pain. Although pain and disturbed sleep are linked, cognitive behavioural therapy for insomnia alone may not be an effective solution for addressing chronic non-malignant pain. Trials of cognitive behavioural therapy for insomnia on a variety of chronic pain patients with disturbed sleep and with long-term follow-up are required to ascertain whether cognitive behavioural therapy for insomnia is an effective intervention to reduce pain and to add to increasing evidence that it is an effective intervention for insomnia in the chronic pain population.
Introduction
Chronic non-malignant pain is defined as non-malignant pain that exists for 3 or more months or pain that lasts beyond the period of expected healing. 1 The majority of those who suffer from chronic pain report poor sleep. 2 Insomnia is a problem with sleep initiation and sleep maintenance and is also associated with daytime neurocognitive impairment. It has a higher prevalence in the chronic pain population than in the general population. 3, 4 The well-established inter-relationship between disturbed sleep and pain severity is also related to mood disturbance, poor sleep hygiene, behavioural priming (previous experience influencing behaviour), cognitive distortions and other cognitive behavioural disturbances. 4, 5 There is strong evidence for the effectiveness of cognitive behavioural therapy in treating pain and insomnia. 6, 7 Cognitive behavioural therapy for insomnia (CBT-I) belongs to a family of psychological interventions that focus on treating insomnia and is a multi-component package that includes stimulus control, sleep restriction, sleep hygiene, sleep education, cognitive restructuring and/or relaxation training. CBT-I improves understanding and clarifies misconceptions individuals have about sleep and insomnia. Components of CBT-I aim to improve sleep habits, address sleep-wake schedule and reduce the incidence of behaviours that interfere with sleep continuity and build-up of sleep pressure. In addition, cognitive restructuring and relaxation helps reduce dysfunctional beliefs and anxiety around sleep.
Considering the relationship between sleep and pain, it can be suggested that treating pain can improve sleep and vice versa. If CBT-I is effective in treating primary insomnia and insomnia comorbid with other conditions, is it effective in treating insomnia comorbid with chronic pain? Does it indirectly reduce pain by improving sleep? On the other hand, if pain disrupts sleep and sleep restriction is associated with enhanced pain perception, 4, 5 does the presence of chronic pain interfere with the response to CBT-I in the chronic pain population? Or does sleep restriction, an essential component of CBT-I, increase pain? These questions becomes more relevant in current practice for treating insomnia after considering the proposed changes in the Diagnostic and Statistical Manual of Mental Disorders -V for the diagnostic criteria of insomnia, in which primary insomnia and insomnia related to another mental/medical disorder will be replaced with insomnia disorder with specification of clinically comorbid conditions, removing the long prevalent differentiation of insomnia based on aetiology. 8 Not many researchers have looked at the efficacy of CBT-I in chronic pain patients on symptoms of insomnia and pain. This review systematically searches and appraises trials exploring this aspect.
Methodology

Objectives
The aim of this review is to explore if CBT-I is an effective treatment of insomnia co-morbid with chronic non-malignant pain and whether treating insomnia with CBT-I in this group modifies pain. This paper, therefore, systematically reviews and appraises randomised controlled clinical trials that specifically assess the effectiveness of CBT-I in individuals with chronic non-malignant pain and co-morbid insomnia, comparing the effectiveness of this intervention with other non-pharmacological treatments or usual care. The outcomes of interest are limited to change in symptoms of insomnia as the primary outcome and pain perception as the secondary outcome. Thus, the objectives can be summarised as follows: 1) Is CBT-I effective in improving symptoms of insomnia in individuals who have insomnia comorbid with chronic pain? 2) Is CBT-I effective in improving pain in individuals who have insomnia co-morbid with chronic pain?
Search strategy
Studies were identified by searching electronic databases; scanning references of review articles and eligible studies; and contacting authors of studies that appeared to meet the criteria but where full text was not available, i.e. conference abstracts or thesis abstracts ( Figure 1 ). However, authors were not contacted for studies that were available as full text for raw data due to the limitations of this assignment. The NHS library search engine was used to search four databases, namely Medline, EMBASE, PSYCINFO and CINHAL. The Cochrane library and Cochrane register of trials was searched to identify trials and systematic reviews on this topic and references of these studies were searched to identify relevant studies. The search strategy is depicted in Table 1 . The search was restricted to English-language articles and published studies. Grey literature was not searched. A time limit was placed from 1990 to 2012 on EMBASE but the other databases did not have a time limit. No age limit was specified. The search was conducted between 12 and 16 June 2012.
Inclusion criteria
The inclusion criteria for the study were as follows: 
Exclusion criteria
The exclusion criteria were as follows:
1. Studies in which the participants have the presence of another sleep disorder other than insomnia in the study group, which is not effectively treated. 2. Studies in which malignant (cancer-related) pain participants are included. 3. Studies for which the control arm has a pharmacological intervention. 4. Studies for which measuring pain and insomnia outcomes are not part of the objectives and have been included in the analysis as a post-hoc finding.
Results
Results of the search
A total of 1715 studies were identified from the database search. The titles of these articles were read to identify those that looked at insomnia, cognitive behaviour therapy and pain, and this resulted in selecting 29 articles from PSYCINFO, five from CINHAL, 25 from MEDLINE, eight from EMBASE and seven from Cochrane respectively. Further, titles and abstracts of these studies were read. PSYCINFO, CINHAL, EMBASE, MEDLINE and Cochrane produced one, three, three, three and five studies, respectively. These included duplicates. Ten studies were shortlisted from the above search. When read in full, six out of the ten articles did not meet all the inclusion and exclusion criteria or could not be included for other reasons (see Appendix 1) . Four studies met all the inclusion and exclusion criteria. [9] [10] [11] [12] Findings of the four studies that met all the criteria are reported in Tables 2 and 3 . Of the four studies selected, three studied chronic pain, either spinal/ limb 9, 11 or arthritic in origin, 12 whereas one studied fibromyalgia patients. 10 One study extracted its data from a parent study done 4 years earlier and hence the latter study was used to supplement information for the objectives of the review. 12, 13 Evaluation of selected papers Quality assessment of the studies was done using the CONSORT checklist for reporting clinical trials, Cochrane risk of bias tool and the quality assessment scale for psychological interventions. [14] [15] [16] Overall, all four clinical trials were of good quality. All studies had a small unexplained sample size. Jungquist et al. 11 and Vitiello et al. 12 described the randomisation and blinding process in detail. 11, 12 Apart from Vitiello et al., other studies did not clearly describe the study settings. All studies used the same therapists (who varied in skill level across the studies) for the experimental and control interventions/contact. Three studies used multi-faceted cognitive behavioural therapy, 9, 11, 12 whereas Edinger et al. 10 focused on the behavioural component (stimulus control and sleep restriction) of CBT-I. Jungquist et al. 11 and Edinger et al. 10 provided individual therapy whereas Currie et al. 9 and Vitiello et al. 12 provided group therapy in the intervention. Outcome measures are detailed later. There were no changes in outcomes along the duration of each study. Similarities between groups were controlled for, 12 acknowledged 10, 11 or avoided. 9 A clear description of the statistical methods used and their appropriateness for the purpose of the study was given in each study. The number of participants added up in all studies and losses were accounted for. There was a minor discrepancy in the parent study of Vitiello et al. 12 where one participant was misrepresented in analysis, but this is unlikely to have affected the results. 13 Although intention to treat was followed in principle by most, Edinger et al. 10 did not include the baseline measures of those who did not complete treatment. Results were reported as means of improvement with standard deviations and also as effect sizes by Jungquist et al. 11 and Vitiello et al. 12 Although p-values were reported, none of the studies reported the changes in outcomes/effect sizes with its confidence intervals.
Assessment of patients
The total combined sample size for these studies was 186 participants. All participants were adults with the Vitiello et al. 12 
Measurement of outcomes
Sleep latency, sleep efficiency, wake after sleep onset (WASO), total sleep time and total wake time were the major insomnia variables measured as outcomes in the four studies. These were primarily measured 
Primary outcomes
SE, SL and WASO showed an improvement post treatment and at follow-up (3 months) in the CBT-I group that was greater and significant than in the WLC group. The major improvement indicators for CBT-I were (as measured on sleep diary): SE: 72% to 85% to 84% SL: 54.7 min to 28.1 min to 27.8 min WASO: 88.9 min to 40.2 min to 40.6 min PSQI: 13.6 to 8.8 to 7.9 Actigraphy activity levels were significantly reduced in the CBT group post treatment but not at followup. There was a significant reduction in activity levels in the CBT group compared with the WLC group at post treatment but not at follow-up. A significantly higher number of CBT group participants were classed as clinically improved in each of the three definitions compared with the WLC group but only five in the CBT group and none in the WLC group met all three criteria for significant improvement.
Secondary outcomes
There was no significant difference in pain scores on the MPI-PS scale post treatment or at follow-up in the CBT group as compared with the WLC group. There was a significant time effect across post treatment and at follow-up for both groups but no between-group difference and no increase in pain. BDI score changes were insignificant. Primary outcomes SE, SL and TWT showed an improvement post treatment and at follow-up (6 months) in the CBT-I group that was greater and significant as compared with the UC group. On actigraphy, this significance was noticed only in sleep latency. However, SH therapy did not differ in any measure from either CBT-I group or UC group independently. The major improvement indicators for CBT-I (as measured on the sleep diary) were as follows: SE: 80.6% to 88% to 89% SL: 33 min to 17 min to 15.8 min TWT: 103.1 min to 59.8 min to 53.6 min A significantly higher number of CBT patients (57%) were classed as clinically improved as compared with SH (p = 0.05) and UC (p = 0.007) based on three definitions of clinical improvement. This improvement was noticed both in the sleep diary and on actigraphy findings. Secondary outcomes Though a significant group × time effect was observed for secondary outcomes including pain scores, no significant change was observed in the pain ratings on MPQ and BPI scores in the CBT group in comparison with the UC or SH group. However, a significant reduction in pain was noted for the SH group in comparison with the UC group on paired comparison 13 Insomnia symptoms were measured using the insomnia symptom questionnaire 5 and insomnia severity index. 11 Pain was measured on various valid questionnaires, including the Multidimensional Pain Inventory (MPI), 9, 11 McGill Pain Questionnaire (MPQ), 10 Short-form MPQ, 12 Pain Disability Index (PDI), 11 Brief Pain Inventory (BPI), 10 SF-36 bodily pain subscale 12 and a 0-10 Likert scale for pain. 11 Other variables measured emotional distress, fatigue and other daytime consequences, but are beyond the scope of this review's objectives.
Change in sleep and pain parameters
The effectiveness of CBT-I was examined in comparison with control groups that included waiting list controls (WLCs), usual treatment, sleep hygiene and attentional control, with Edinger et al. using three groups: experimental (CBT-I), sleep hygiene and usual care for fibromyalgia patients. Currie et al. demonstrated significant improvements in sleep latency, sleep efficiency and WASO across time and in comparison with WLC in the CBT-I group. 9 Sleep quality improved significantly in both groups post treatment, but at follow-up only the CBT-I group showed statistically significant improvement. Betweengroup analyses revealed that sleep quality in the CBT-I group was significantly better than in the WLC group across time. 9 Edinger et al. demonstrated significant improvement in sleep efficiency, sleep latency and total wake time (from sleep logs) across time and in comparison with usual care in the CBT-I group. 10 However, the sleep hygiene group did not differ from the other groups. For actigraphy, this significant improvement was noticed only for sleep latency. Edinger et al. also measured night-to-night variability across sleep variables and reported less variability in CBT-I group. 10 This was not an outcome of interest for this review. Jungquist et al. reported a significant improvement in sleep efficiency, sleep latency, WASO and number of awakenings in CBT-I group as compared with the control group, as well as in sleep continuity in the insomnia severity index scores in the CBT-I group. 11 Vitiello et al. demonstrated a significant improvement in sleep latency, WASO and sleep efficiency post treatment and at 1-year follow-up in the CBT-I group, and also an improvement in total sleep time at 1-year follow-up in the CBT-I group. 12 This significance at follow-up also persisted when the CBT-I group included those who crossed over from control to CBT-I at the end-of-treatment phase of the study.
Two studies measured clinical significance. 9,10 Currie et al. 9 defined clinical improvement (good sleepers) as sleep latency or WASO < 30 min, sleep efficiency ≥ 85% and PSQI < 6. A significantly higher number (p < 0.05) of CBT-I participants met either criteria as compared with controls, but only 16% of CBT-I participants met all three criteria. None of the WLC participants met all three criteria. The above improvements persisted at follow-up. Edinger et al. 10 adopted a slightly different set of criteria for good sleepers, i.e. total sleep time ≥ 6.5 h, total wake time < 60 min (45 min for actigraphy) and sleep efficiency ≥ 85%. Here, 57% of CBT-I participants as compared with 17% sleep hygiene and 0% usual treatment participants met either criteria for good sleepers post treatment. The findings were similar for actigraphy (43% CBT-I, 7% sleep hygiene, 0% usual treatment participants).
Jungquist et al. 11 demonstrated a significant improvement in pain interference subscale of the MPI for the experimental group. Vitiello et al. demonstrated a significant improvement in the SF-36 pain subscale across post treatment for the experimental group (p = 0.01). Vitiello et al. also reported a significant improvement in the MPQ score across follow-up for the CBT-I group, including crossovers. 12 They also reported a non-significant improvement trend for pain on the MPQ at post treatment for the CBT-I group (p = 0.029). 12 Edinger et al. reported a significant improvement in pain (MPQ and BPI scores) in the sleep hygiene group as compared with the usual control group (p = 0.02 and p = 0.04). This difference did not exist for the CBT-I group. 9 Though Currie et al. showed that pain ratings across the whole sample were significantly lower post treatment and at follow-up (p = 0.001), there were no significant differences between the CBT-I and control group. 8 Within-group and between-group effect sizes of each study for sleep efficiency, sleep latency and WASO are given in Table 4 . These consistently improved across all four studies in the CBT-I group in comparison with the control group. A weighted mean calculation was done to measure the overall effect size for each variable. However, these effect sizes should be looked at with caution because of the heterogeneity of these studies. The effect sizes for pain measures in Currie et al., Edinger et al. and Vitiello et al. were insignificant (i.e. small, < 0.4), although mean scores for all showed a trend towards improvement in pain for the CBT-I group as compared with the control. 9, 10, 12 Over a 1-year follow-up in the CBT-I group, including cross-overs, Vitiello et al. reported a significant improvement in MPQ scores, although the effect size remained small. 12 Jungquist et al. observed a between-group medium effect size for the MPQ pain-interference scale and PDI (effect size > 0.6), whereas the score on the MPI pain intensity subscale and on the average daily pain scale was < 0.6. 11
Discussion
The main limitations of this review are that the sample sizes used in the studies are small and the pain populations quite variable. The results indicate that CBT-I is effective in improving insomnia symptoms in individuals with co-morbid chronic pain. Table 5 reports weighted means of the effect sizes of each variable for all the studies combined. As the four studies are heterogeneous, it is not ideal that the effect sizes of the four studies be combined using weighted means (i.e. fixed-effects model). However, these results are still meaningful and provide useful information about the effectiveness of CBT-I in improving insomnia in a broad range of chronic pain patients. The combined within-group effect sizes of CBT-I for improvement in sleep latency, sleep efficiency and WASO is high, all > 1. This is in contrast to the weighted mean of the effect sizes for the control arm, i.e. all < 0.2. The betweengroup effect sizes of the three variables compared the post-treatment effect size for the intervention and control group. The weighted mean for this shows that the largest effect size was for sleep latency followed by sleep efficiency and WASO, with the latter two variables in the medium range. A quality appraisal of the four studies suggests that the Jungquist et al. study, which shows the largest effect sizes for all sleep variables, also has the highest score on the quality assessment tool for psychological interventions and Cochrane risk of bias tool. 11, 14, 15 Although pain severity, as measured in the four studies, showed a trend towards improvement in pain, not all studies showed a statistically significant improvement on treatment with CBT-I. The lack of significant improvement in pain can be explained in several ways. A larger sample size could have possibly made the observed trend of improvement in pain more significant in each study. It is also likely that the short duration of follow-up in the Currie et al. study and no follow-up post-treatment in the Jungquist et al. study could have influenced the overall significance of the findings. This is possible because chronic pain resolution after improvement in sleep takes longer, unlike the immediate effects observed in sleep parameters. Vitiello et al. followed up participants for 1 year and reported a significant improvement in the MPQ scores in those who received CBT-I unlike changes found post treatment. This is an indication that perhaps long-term follow-up with a larger sample size would give more meaningful results for pain improvement with CBT-I. However, the effect sizes for improvement in pain in the latter study were small (~ 0.3). This suggests that, although there was a significant improvement in pain scores with CBT-I on follow-up, the size of the change was not very meaningful when translated to actual patient improvement. Jungquist et al. have provided follow-up data for their study separately and report that, although the sleep improvements following CBT-I in chronic pain patients are sustained for at least 6 months post treatment, the effects on subjective improvement in pain remain less convincing. 18 After considering the inter-relationship of sleep and pain, it would be natural to assume that an improvement in sleep parameters would result in a significant improvement in pain. Why this was not observed could be explained at a biological and psychological level. More than one-third of the participants in both groups were prescribed analgesics with around 70% in the Edinger et al. study prescribed analgesics or antidepressants. This would be an expected situation for those with chronic pain. Although all studies controlled for this confounding factor, the use of these agents per se could be a reason why pain did not improve despite improvement in macro-aspects of sleep. Analgesics such as antidepressants and opioids have varied effects on sleep macro-architecture and also affect the microarchitecture (e.g. rapid eye movement suppression by antidepressants and opioids). 19, 20 Little is known about the impact of these changes on the analgesic effects of commonly used analgesics. It is likely that the improvement in sleep noted in the sleep macro-architecture by CBT-I was not accompanied by an improvement in the micro-architecture, and hence resulted in minimal improvement in pain. Although this is a speculation, it is also a possibility. In addition to this, it is likely that long-term changes brought about by a chronic pain condition are irreparable by only improvement in sleep. 11 From a psychological perspective, poor sleepers with chronic pain are also more likely to have dysfunctional beliefs about sleep that are similar to those found in individuals with primary insomnia. 21 Chronic pain patients endorse dysfunctional beliefs about sleep and pain and attribute their poor sleep to pain, hence failing to use effective sleep improving measures. 21 A Cochrane review on CBT for chronic pain reports that CBT for pain has a small to medium effect size in reducing pain. 6 This effect size is similar to that of CBT-I on pain, as noted above. Haynes has argued that because of the limited effectiveness of cognitive behavioural approaches to pain management in these two situations, there is little beyond mild benefits to achieve from CBT as far as chronic pain is concerned. 22 However, considering that chronic pain patients have dysfunctional beliefs about pain and sleep, which contribute to maintaining both, it is worthwhile to suggest that a cognitive approach that addresses cognitive distortions for sleep and pain combined with a behavioural approach for both may have an additive effect and perhaps increase the effectiveness of CBT for poor sleepers with chronic pain.
Since this literature review was conducted, other researchers have studied the impact of CBT-I on sleep and pain parameters in the chronic pain population. Two studied the effect of a combined model of CBT that addresses both pain and insomnia in comparison with either CBT for insomnia, pain and control 23 or CBT for pain and a control group. 24 Another reports the long-term follow-up data of the Jungquist et al. study included in this review. 18 These studies address some of the questions raised by this systematic review. A further clinical trial looking at the effect of treatment of insomnia on pain has been recently completed in the UK, but the findings have so far not been reported.
Conclusion
Only four studies were identified and all were heterogeneous. This limits the conclusions that can be drawn from this review. However, it demonstrates that CBT-I produces statistically and clinically significant improvement in insomnia in patients with comorbid chronic pain. It also suggests that CBT-I may contribute to some improvement in pain; however, the lack of significance of these findings makes it difficult to state this with confidence. From the practice perspective, the effectiveness of CBT-I for this group suggests that it should not be overlooked as an option for poor sleepers with chronic pain. From the research perspective, future studies should continue to explore:
-The effectiveness of CBT-I in poor sleepers with both chronic pain and psychiatric illness in view of the fact that this will make the results more generalisable to the real-world chronic pain population where emotional difficulties are highly prevalent. -Developing a CBT model that addresses both pain and sleep and investigate its effectiveness in this group for both sleep and pain. More recently, researchers have studied the effectiveness of a hybrid CBT model aimed at addressing both insomnia and pain in this population. 23 
